Bart Henderson is an operating partner at Flagship Pioneering, and the former CEO and co-founder of Torque, now Repertoire Immune Medicines. Under Bart’s leadership, Torque significantly advanced its cellular immunotherapy pipeline, initiating the company’s first clinical trial, receiving Fast Track designation from the FDA, and collaborating with Thermo Fisher Scientific to build a state-of-the-art manufacturing facility for Torque’s T cell immunotherapies.
Previously, Bart was founder and president of Rhythm and its subsidiary Motus which together completed successful Phase II clinical trials for two metabolic products: setmelanotide which was granted Breakthrough Designation for genetic obesity and recently filed a New Drug Application (NDA) with the FDA; and relamorelin which was acquired by Allergan (with Motus) and is now in Phase 3 clinical trials. He was a founding employee and chief business officer of Radius, where he built the pipeline and launched the first clinical trial for Tymlos®, now approved for the treatment of osteoporosis. Bart was entrepreneur-in-residence at MPM Capital where he acquired the first oncology product for Solasia KK, which is now marketed in several Asian countries. He led business development at Microbia (now Ironwood Pharmaceuticals) and was head of sales and marketing at Vertex which launched its first product and significantly expanded its pipeline during his tenure. Bart previously held marketing management positions at Amgen and Merck.
Bart received an M.B.A. from Dartmouth’s Tuck School of Business and a B.A. from Amherst College.